|
Market Closed -
Nyse
21:00:02 12/02/2026 GMT
|
5-day change
|
1st Jan Change
|
|
12.99 USD
|
-20.45%
|
 |
-23.81%
|
+2.77%
|
|
11-11 |
Morgan Stanley Upgrades RXO to Overweight From Equalweight
|
MT
| |
11-07 |
UBS Adjusts Price Target on RXO to $15 From $17, Maintains Neutral Rating
|
MT
| |
03/10/25 |
UBS Adjusts RXO Price Target to $17 From $15, Maintains Neutral Rating
|
MT
| |
08/08/25 |
UBS Lifts Price Target on RXO to $15 From $14, Maintains Neutral Rating
|
MT
| |
07/07/25 |
Morgan Stanley Lowers Price Target on RXO to $21 From $23, Keeps Equalweight Rating
|
MT
| |
16/05/25 |
BofA Securities Adjusts RXO Price Target to $18 From $15, Maintains Neutral Rating
|
MT
| |
08/05/25 |
UBS Cuts Price Target on RXO to $14 From $24, Keeps Neutral Rating
|
MT
| |
04/04/25 |
Oppenheimer Downgrades RXO to Market Perform From Outperform
|
MT
| |
13/03/25 |
Truist Securities Initiates Coverage on RXO With Buy Rating, $24 Price Target
|
MT
| |
07/03/25 |
Deutsche Bank Initiates RXO With Hold Rating, $19 Price Target
|
MT
| |
12/11/24 |
Citigroup Downgrades RXO to Neutral From Buy, Price Target is $33
|
MT
| |
14/10/24 |
BofA Adjusts Price Target on RXO to $31 From $30, Maintains Neutral Rating
|
MT
| |
09/10/24 |
Citigroup Initiates RXO at Buy With $33 Price Target
|
MT
| |
08/08/24 |
UBS Adjusts RXO Price Target to $31 From $22, Maintains Neutral Rating
|
MT
| |
08/08/24 |
Oppenheimer Adjusts RXO Price Target to $31 From $22, Maintains Outperform Rating
|
MT
| |
22/07/24 |
BofA Securities Adjusts Price Target on RXO to $32 From $22, Maintains Neutral Rating
|
MT
| |
16/07/24 |
Barclays Raises Price Target on RXO to $30 From $24, Maintains Overweight Rating
|
MT
| |
09/07/24 |
JPMorgan Adjusts Price Target on RXO to $25 From $16, Maintains Underweight Rating
|
MT
| |
25/03/24 |
Susquehanna Raises RXO Price Target to $16 From $15, Maintains Negative Rating
|
MT
| |
13/02/24 |
Oppenheimer Trims RXO Price Target to $22 From $23, Maintains Outperform Rating
|
MT
| |
09/02/24 |
UBS Adjusts RXO Price Target to $22 From $20, Maintains Neutral Rating
|
MT
| |
09/02/24 |
Susquehanna Adjusts Price Target on RXO to $15 From $18, Maintains Negative Rating
|
MT
| |
16/01/24 |
BofA Securities Adjusts Price Target on RXO to $25 From $21, Maintains Buy Rating
|
MT
| |
10/01/24 |
Stifel Adjusts RXO's Price Target to $22 From $20, Maintains Hold Rating
|
MT
| |
10/01/24 |
Vertical Research Downgrades RXO to Hold From Buy, Trims Price Target to $23 From $24
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
